Takeda Pharmaceutical (TAK) said Tuesday it signed a master agreement with Astellas Pharma and Sumitomo Mitsui Banking to establish a joint venture company, Ciconia Bioventures.
Ciconia will cover the entire process from early drug discovery research to the formation of biotech startups with the aim of turning innovative technologies originating in Japan into clinical applications, the company said.
"Ciconia will evaluate early development stage seeds, establish its own company based on the selected seeds, raise funds worldwide and pursue global product development," Ciconia founder and Chief Executive Toshio Fujimoto said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。